Condition
Carcinoma, Non-small-cell Lung|Mesothelioma|Pancreatic Neoplasms
Estimated Enrollment: 59
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: GN15ON133|2015-003928-31
Study First Received: April 20, 2016
Last Updated: June 14, 2016
Estimated Primary Completion Date: June 2018
Primary Outcome Measures:
Adverse events (AEs) using CTCAE v4.03 (to determine dose limiting toxicities (DLTs) and maximum tolerated dose (MTD))|Objective response rate (ORR), using best objective response by irRECIST|Duration of response (DoR)|Progression free survival (PFS) using irRECIST|Overall survival|Change in FAK Y397 phosphorylation|Change in immune cell infiltrate
Sponsors and Collaborators:
NHS Greater Glasgow and Clyde|University of Glasgow|Cancer Research UK|Merck Sharp & Dohme Corp.|Verastem, Inc.|University of Edinburgh|University of Southampton|University of Leicester|Queen’s University, Belfast
Website Link: https://ClinicalTrials.gov/show/NCT02758587
